XML 27 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Discontinued Operations (Details) - USD ($)
shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 27, 2015
Feb. 27, 2015
Feb. 10, 2015
Apr. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Proceeds from the disposition of business             $ 230    
Gain on sale of Mylan shares             207    
Proceeds from the sale of Mylan N.V. shares             2,290    
After Tax Gain         $ 16   1,752    
Pretax gain on sale of discontinued operations             2,837    
Trade receivables, net         58   58   $ 498
Total inventories         48   48   254
Prepaid expenses, deferred income taxes, and other receivables         33   33   140
Current assets held for disposition         139   139   892
Net property and equipment         2   2   125
Earnings from discontinued operations, net tax benefits         (16) $ 100 1,745 $ 293  
Intangible assets, net of amortization                 804
Goodwill                 950
Deferred income taxes and other assets                 55
Non-current assets held for disposition         2   2   1,934
Total assets held for disposition         141   141   2,826
Trade accounts payable         337   337   423
Salaries, wages, commissions and other accrued liabilities         19   19   257
Current liabilities held for disposition         356   356   680
Post-employment obligations, deferred income taxes and other long-term liabilities                 108
Non-current liabilities held for disposition                 108
Total liabilities held for disposition         356   $ 356   $ 788
Developed markets branded generics pharmaceuticals business                  
Value of shares received for sale of generics pharmaceuticals business to Mylan Inc $ 5,770 $ 5,770              
Period of notice require to terminate manufacturing supply of products             2 years    
After Tax Gain   $ 1,600              
Intangible assets, net of amortization         738   $ 738    
Goodwill         894   $ 894    
Developed markets branded generics pharmaceuticals business | Minimum                  
Period for providing manufacturing supply of products             3 years    
Developed markets branded generics pharmaceuticals business | Maximum                  
Period of transition services             2 years    
Period for providing manufacturing supply of products             10 years    
Animal Health Business                  
Proceeds from the disposition of business     $ 230            
After Tax Gain     $ 130            
AbbVie | Proprietary Pharmaceuticals Business Assets and Liabilities Held for Disposal                  
Prepaid assets         $ 216   $ 216    
AbbVie | Discontinued operations                  
Earnings from discontinued operations, net tax benefits             $ 10 $ 37  
Mylan                  
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc       110.0          
Number of shares in investment sold       40.3          
Mylan | Developed markets branded generics pharmaceuticals business                  
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc 110.0           110.0    
Gain on sale of Mylan shares             $ 207    
Number of shares in investment sold             40.3    
Mylan NV | Developed markets branded generics pharmaceuticals business                  
Percentage of shares received for sale of generics pharmaceuticals business to Mylan Inc 22.00% 22.00%